An observational study in Critical Illness and Sepsis, Severe, sponsored by Children's Hospital of Fudan University. Recruiting at 2 sites in China. Open to participants aged 29 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Children's Hospital of Fudan University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Sepsis by Children's Hospital of Fudan University — 6 open to participants now, 6 under way, none of them phase 3. Sepsis · Children's Hospital of Fudan University.
Among the 10 studies in Sepsis by Children's Hospital of Fudan University, this one is the only one that started in 2024, is one of 9 observational ones, and was the 3rd registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →6 of the 10 studies in Sepsis by Children's Hospital of Fudan University are open now, in 1 country. Recruiting first, the newest first:
Children's Hospital of Fudan University · Sites in China
Ages 29 days–28 yrs
Children's Hospital of Fudan University · Sites in China
Ages 3 mo–18 yrs
Children's Hospital of Fudan University · Sites in China
Ages 29 days–18 yrs
Children's Hospital of Fudan University · Sites in China
Ages 28 days–18 yrs
Children's Hospital of Fudan University · Sites in China
Ages 29 days–18 yrs
By country, each count listing its studies:
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 29 Days to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 200 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 120 across the 1 interventional studies, 80 across the 9 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 94 are open to participants now.
5 of the studies in Sepsis by Children's Hospital of Fudan University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04794595Children's Hospital of Fudan UniversityClinical Features and Outcomes of CBP Versus Non-CBP in Septic Children | 2026-12-30 |
| NCT04961580Children's Hospital of Fudan UniversityPK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection | 2026-12-31 |
| NCT04955210Children's Hospital of Fudan UniversityA Multi-Center Data System and Collaborative Network in China for Severe Infection and Sepsis Children | 2026-12-31 |
| NCT04850456Children's Hospital of Fudan UniversityTreatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm | 2026-12-31 |
| NCT05692011Children's Hospital of Fudan UniversityAN69ST Verse PS in CBP in Septic Children | 2026-12-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 10 studies in Sepsis by Children's Hospital of Fudan University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The inflammatory storm in critically ill patients releases cytokines, causing systemic immune damage, which may be an important cause of multiple organ failure and even death. Inflammatory storms exacerbate the deterioration of the disease in those children. Gamma globulin may be an effective option to control inflammatory storms. However, this preliminary result needs to be verified from reliable and representative RCTs. In our study, we conducted a retrospective study on the use of gamma globulin and an unused control group. At present, the indications of IVIG are mainly focused on the neuromuscular system and the blood system. We hope to establish a more appropriate and operable evaluation table for the suitability of gamma globulin for clinical use.
In severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe secondary hospital-acquired infections. However, the role of gamma globulin therapy in patients with severe infection including sepsis and septic shock is discussed controversially. We intend to retrospectively analyze the efficacy and application evaluation of gamma globulin in severely infected children hospitalized in the intensive care unit. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record. It is expected to provide evaluation basis for clinicians to formulate treatment plans and clinical pharmacists for special comments on the clinical use of gamma globulin.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
This study's planned enrollment of 200 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Browse Sepsis studies →Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 94 are open to participants now.
Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All children hospitalized in PICU of Children's Hospital of Fudan University from January 2022 to December 2023
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human Gamma Globulin
conventional treatment
The death rate of children
The death rate of children in 28 days after their discharged from PICU
Time frame: within 28 days after they discharged from PICU
length of stay in PICU
Time from PICU admission to discharge
Time frame: up to 28 days
CD4+/CD8+
levels of peripheral blood subgroup of T lymphocyte (digital form)
Time frame: Within 3 to 15 days after the start of treatment
C-reactive protein (CRP)
C-reactive protein (digital form)
Time frame: Within 3 to 15 days after the start of treatment
IL-2R
The interleukin-2 receptor (digital form)
Time frame: Within 3 to 15 days after the start of treatment
TNF-alpha
Tumor necrosis factor alpha (digital form)
Time frame: Within 3 to 15 days after the start of treatment
Treg
levels of peripheral blood subgroup of T lymphocyte (digital form)
Time frame: Within 3 to 15 days after the start of treatment
IL-6
The interleukin-6 (digital form)
Time frame: Within 3 to 15 days after the start of treatment
IFN-gamma
Interferon gamma (digital form)
Time frame: Within 3 to 15 days after the start of treatment
Procalcitonin (digital form)
Procalcitonin (digital form)
Time frame: Within 3 to 15 days after the start of treatment
IL-10
The interleukin-10 (digital form)
Time frame: Within 3 to 15 days after the start of treatment
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital of Fudan University →